Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue remains negative
Q1 FY2026 cost of revenue was $211K, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $211K.
Context
- Cost of revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near $211K or moves back toward the trailing-twelve-month quarterly average of $52.75K.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 572K USD
- Year-over-year change
- —
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 572K | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$7.28M CAD | -18.9% | +9.4% | 39.7% |
CBUSCibus, Inc. | LTM Mar 2026 | $1.2M USD | -30.9% | +56.9% | 27.9% |
| LTM Mar 2026 | $936K USD | — | — | 23.8% | |
| LTM Mar 2026 | $593K USD | — | — | — | |
| LTM Mar 2026 | $211K USD | — | — | — | |
| LTM Mar 2026 | $66K USD | -82.3% | — | — | |
| LTM Mar 2026 | $33K USD | -50.0% | — | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$228K USD | -137.1% | — | — |
| Peer median (excluding UNCY) | — | -50.0% | +33.1% | 25.9% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 951K | 675K | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 572K |
| Gross Profit | 0 | 951K | 675K | 0 | (572K) |
| Gross Margin | — | 100.0% | 100.0% | — | — |
| Research & Development | 6.08M | 12.44M | 12.9M | 20.01M | 9.12M |
| Selling, General & Admin | 2.9M | 6.57M | 8.55M | 12.1M | 20.4M |
| Operating Expenses | 8.98M | 19M | 21.45M | 32.12M | 28.95M |
| Depreciation & Amortization | 13K | 161K | 284K | 428K | 572K |
| EBITDA | (9.38M) | (17.89M) | (30.18M) | (36.23M) | (25.91M) |
| EBITDA Margin | — | -1881.3% | -4470.8% | — | — |
| Operating Income | (8.98M) | (18.05M) | (20.77M) | (32.12M) | (29.52M) |
| Operating Margin | — | -1898.2% | -3077.6% | — | — |
| Interest Income | 0 | 0 | 615K | 1.26M | 1.01M |
| Interest Expense | 628K | 6K | 82K | 71K | 71K |
| Other Income / Expenses | (1.04M) | (6K) | (9.77M) | (4.61M) | 2.96M |
| Income Before Tax | (10.02M) | (18.06M) | (30.54M) | (36.73M) | (26.56M) |
| Pre-Tax Margin | — | -1898.8% | -4525.0% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (10.02M) | (18.06M) | (30.54M) | (36.73M) | (26.56M) |
| Net Margin | — | -1898.8% | -4525.0% | — | — |
| EPS (Basic) | (8.60) | (1.20) | (1.28) | (5.60) | (1.67) |
| EPS (Diluted) | (8.60) | (1.20) | (1.28) | (5.60) | (1.67) |
| Weighted Avg Shares | 1.17M | 1.51M | 2.45M | 6.7M | 158.87M |
| Weighted Avg Shares (Diluted) | 1.17M | 1.51M | 2.45M | 6.7M | 158.87M |
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.